EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trial

Sebastiano Buti, Se-Eun Kim, Michele Maffezzoli iD, Mohamad E Allaf, Giulia Claire Giudice, Giuseppe L Banna, Satoru Taguchi iD, Naomi B Haas iD, Michael A Carducci

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag041 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Sebastiano Buti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medicine and Surgery Department, University of Parma, Parma, 43126, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute of the National Institutes of Health, NCI NIH HHS, ECOG-ACRIN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The GRANT score is one of the prognostic models recommended by international guidelines to refine recurrence risk stratification in patients with surgically treated renal cell carcinoma (RCC) and integrates age, tumor size, grade, and nodal status. In this study, we aimed to validate the GRANT score within the ECOG-ACRIN EA8143 PROSPER prospective trial.

Methods

We conducted a validation analysis of the GRANT score within the phase III randomized EA8143 PROSPER study of perioperative nivolumab in surgically treated RCC. Patients were classified into two risk groups, favorable (0–1 risk factors) vs unfavorable (2–4 risk factors). Relapse-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Model discrimination were evaluated using Harrell’s C-index.

Results

Among 714 patients included, 58.3% were favorable and 41.7% unfavorable based on the GRANT score. Patients in the favorable group had a significantly longer median RFS (61.1 vs 36.9 months; HR: 0.36, 95%CI: 0.27–0.48, p < 0.001) and OS (median not reached, HR: 0.25, 95%CI: 0.15–0.42, p < 0.001) compared to patients in the unfavorable group. The c-index was 0.63 and 0.66 for RFS and OS, respectively. A better prognostic performance was observed among non-clear cell RCC for both RFS (HR: 0.13, 95%CI: 0.05–0.33, p < 0.001; c-index: 0.74) and OS (HR: 0.14, 95%CI: 0.04–0.50, p < 0.001; c-index 0.74).

Conclusions

The GRANT score was prospectively validated in the PROSPER study, demonstrating prognostic value for both RFS and OS, especially in non-clear RCC, further supporting its use in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansFemaleMalePrognosisProspective StudiesAgedMiddle AgedNeoplasm GradingAge FactorsNivolumab

Stichwörter der Autor:innen

GRANTPROSPERimmunotherapyneoadjuvantnivolumabperioperativeprognosisrenal cancersurgery

Substanzen

Nivolumab

Autor:innen und Institutionen

  • Medicine and Surgery Department, University of Parma, Parma, 43126, Italy.
  • Medical Oncology Unit, University Hospital of Parma, Parma, 43126, Italy.
  • Department of Data Science, Dana-Farber Cancer Institute/ECOG-ACRIN Biostatistics Center, Boston, MA, 02215, United States.
  • Department of Oncology Unit, Portsmouth University Hospital NHS Trust, Portsmouth, PO6 3LY, United Kingdom.
  • Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, United States.
  • Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, 42122, Italy.

ORCID-Profile: Michele Maffezzoli, Satoru Taguchi, Naomi B Haas

Förderung

  • National Cancer Institute of the National Institutes of Health
  • NCI NIH HHS
  • ECOG-ACRIN

Zitieren

APA

Buti, S., Kim, S. E., Maffezzoli, M., Allaf, M. E., Giudice, G. C., Banna, G. L., Taguchi, S., Haas, N. B., & Carducci, M. A. (2026). A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trial. The Oncologist. https://doi.org/10.1093/oncolo/oyag041

Vancouver

Buti S, Kim SE, Maffezzoli M, Allaf ME, Giudice GC, Banna GL, et al. A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trial. The Oncologist. 2026. doi:10.1093/oncolo/oyag041

BibTeX
@article{Buti2026,
  author = {Buti, Sebastiano and Kim, Se-Eun and Maffezzoli, Michele and Allaf, Mohamad E and Giudice, Giulia Claire and Banna, Giuseppe L and Taguchi, Satoru and Haas, Naomi B and Carducci, Michael A},
  title = {A prospective external validation of the GRade, Age, Nodes and Tumor (GRANT) score in the ECOG-ACRIN EA8143 PROSPER trial},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag041}
}
Kostenlos starten →